NeuroSense Therapeutics Ltd. (NRSN)
NRSN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.49
+0.29% on the day
Market cap
$6.6M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NRSN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2021 |
| SEC CIK | 0001875091 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-01-29 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-31 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 311 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| NRSNW | NeuroSense Therapeutics Ltd. Warrant | $0.0099 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACXP | Acurx Pharmaceuticals Inc. | $1.20 | -6.25% | $6.7M |
| ALZN | Alzamend Neuro Inc. | $1.35 | +3.05% | $6.5M |
| FBLG | FibroBiologics Inc. | $0.9599 | -4.01% | $6.5M |
| SKYE | Skye Bioscience Inc. | $1.53 | -3.17% | $6.8M |
| LGVN | Longeveron Inc. | $2.15 | -12.24% | $6.9M |
| TRAW | Traws Pharma Inc. | $0.4101 | -1.42% | $6.3M |
| ENVB | Enveric Biosciences Inc. | $1.40 | -4.76% | $6.3M |
| APUS | Apimeds Pharmaceuticals US Inc. | $4.62 | -11.15% | $7.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier